Skip to main content
TipRanks
Go Ultimate75% OFF

Isofol Medical AB (ISOFOL) AI Stock Analysis

1 Followers
SE:ISOFOL

Isofol Medical AB

(Nasdaq OMX AB:ISOFOL)

Select Model
Rating:53Neutral
Price Target:SEK 1.00â–²(1.01% Upside)
Action:reiterated
Date:11/14/26

The overall score of 53 reflects a high-risk, early-stage biotechnology company. The primary strengths are its debt-free balance sheet and significantly improved cash flow management, which provide a stable financial runway. Positive technical trends offer some market support. These are heavily offset by the critical weaknesses of having no revenue, persistent net losses, and a negative P/E ratio, which underscore the company's pre-commercial stage and speculative nature.

Positive Factors
Focused oncology pipelineA focused oncology candidate gives Isofol a defined development strategy rather than a broad, unfocused research portfolio. If clinical and regulatory objectives are achieved, arfolitixorin could support a scalable product opportunity within established chemotherapy treatment pathways.
Negative Factors
No meaningful commercial revenueThe absence of meaningful revenue confirms that Isofol has not yet established a commercial earnings base. Until a product is approved and adopted, operating performance will remain tied to development progress rather than recurring customer demand or product sales.

Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)

-25%0%25%50%75%100%125%SE:ISOFOL+34.33%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 306.07M
Dividend Yield
―
Average Volume (3M)
1.25M
Price to Earnings (P/E)
-5.3
Beta (1Y)
-0.31
Revenue Growth
―
EPS Growth
35.02%
Country
Sweden
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Isofol Medical AB Business Overview & Revenue Model

Company Description

Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is pre...

How the Company Makes Money

As a clinical-stage biotechnology company, Isofol Medical AB has historically not generated recurring revenue from product sales (no approved commercial products). Its funding has therefore primarily come from external financing rather than operating...

Isofol Medical AB Financial Statement Overview

Summary

The company is pre-revenue with persistent net losses, which is a major weakness. However, the balance sheet is debt-free with a solid equity cushion, and cash flow management has improved dramatically, bringing free cash flow near breakeven. The overall financial health is mixed, balancing a lean, conservative structure against the lack of revenue generation.

Income Statement

5Very Negative

Balance Sheet

65Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000721.00K12.80M22.41M
Gross Profit00-38.73M-34.41M-165.71M-174.31M
EBITDA-57.13M-54.76M-47.21M-37.02M-159.73M-198.49M
Net Income-56.63M-54.17M-43.49M-37.07M-159.79M-200.25M
Balance Sheet
Total Assets118.56M129.40M98.42M140.60M213.46M401.36M
Cash, Cash Equivalents and Short-Term Investments114.83M126.99M96.16M138.15M190.58M379.45M
Total Debt00003.95M1.65M
Total Liabilities23.55M21.52M20.47M19.16M54.99M83.13M
Stockholders Equity95.01M107.87M77.94M121.43M158.48M318.23M
Cash Flow
Free Cash Flow-700.00K-51.94M-41.99M-52.54M-190.97M-188.43M
Operating Cash Flow-52.63M-51.94M-41.99M-52.54M-190.97M-188.43M
Investing Cash Flow000101.00K00
Financing Cash Flow101.96M84.07M0023.00K450.48M

Isofol Medical AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.99

Price Trends

50DMA0.97Positive
100DMA0.88Positive
200DMA0.78Positive

Market Momentum

MACD0.00Positive
RSI44.67Neutral
STOCH6.75Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Neutral. The current price of 0.99 is below the 20-day moving average (MA) of 1.21, above the 50-day MA of 0.97, and above the 200-day MA of 0.78, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 44.67 is Neutral, neither overbought nor oversold. The STOCH value of 6.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ISOFOL.

Isofol Medical AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ISOFOL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 360.89M1.9063.09%―――
SE:ISOFOLSE:ISOFOL53NeutralSEK 306.07M-5.28-58.68%――35.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ELICSE:ELIC48NeutralSEK 162.84M-6.97-56.09%――14.10%
SE:IMMUSE:IMMU48NeutralSEK 217.58M-1.96-19.14%――13.06%
SE:ONCOSE:ONCO44NeutralSEK 729.43M-2.60――65.37%43.28%
SE:BINVSE:BINV37UnderperformSEK 142.80M-0.28-128.54%―-83.67%-50.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:ISOFOLSE:BINVSE:ONCOSE:ELICSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ISOFOL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ISOFOLIsofol Medical AB0.990.2941.23%
SE:BINVBioInvent International AB2.09-27.96-93.04%
SE:ONCOOncopeptides AB1.64-3.30-66.83%
SE:ELICElicera Therapeutics AB2.46-2.70-52.27%
SE:IMMUImmunicum AB3.50-1.49-29.79%
SE:CANTACantargia AB1.29-1.94-60.03%

Isofol Medical AB Corporate Events

Isofol Sets SEK 0.95 Exercise Price for TO2 Warrants

Nov 13, 2026

Isofol Medical AB has set the exercise price for 39,863,928 TO2 warrants issued in connection with its June/July 2025 rights issue at SEK 0.95 per share. The price represents 70% of the company’s volume-weighted average share price during 2–13 Novemb...

Isofol Reports Interim Results and Arfolitixorin Study Update

Nov 12, 2026

Isofol reported net revenue of kSEK 0 in both the third quarter and January–September 2026. The third-quarter loss was kSEK 11,995, while the nine-month loss reached kSEK 42,785; cash and cash equivalents stood at kSEK 98,087 on September 30.The comp...

Isofol Reports Preliminary Disease Control in Arfolitixorin Trial

Nov 10, 2026

Isofol Medical is a clinical-stage biotechnology company focused on cancer treatments. Its drug candidate, arfolitixorin, is a next-generation folate treatment designed to enhance established therapies for solid tumors and is being evaluated in metas...

Isofol Sets AGM 2027 Nomination Committee as Cancer Drug Development Advances

Oct 28, 2026

Isofol Medical AB, a Gothenburg-based biotech listed on Nasdaq Stockholm, develops cancer therapies aimed at improving quality of life and prognosis for patients with severe malignancies. Its lead candidate arfolitixorin is designed to boost the effi...

Isofol schedules investor updates to showcase new data on cancer drug arfolitixorin

Oct 13, 2026

Isofol Medical will host an Investor & Scientific Update in Stockholm on November 12, followed by a summary meeting in Gothenburg on November 13, to present new data and scientific insights on its lead drug candidate arfolitixorin. The events, featur...

Isofol to Highlight Cancer Drug Candidate at BioStock Investor Meetings

Sep 22, 2026

Isofol Medical AB, a Gothenburg-based clinical-stage biotech listed on Nasdaq Stockholm, is developing arfolitixorin, a proprietary next-generation folate treatment intended to enhance the effectiveness of established therapies for solid tumors. The...

Isofol Deepens Arfolitixorin Push as Cash Reserves Bolster Pre-Revenue Pipeline

Aug 25, 2026

Isofol Medical AB reported its interim results for January to June 2026, highlighting a continued strategic focus on clinical development rather than commercial revenues. The company remains pre-revenue, posting a first-half loss of kSEK -30,790, but...

Isofol expands arfolitixorin cancer trial to accelerate patient recruitment

Aug 24, 2026

Isofol Medical is expanding its phase Ib/II clinical study of arfolitixorin in colorectal cancer by adding new trial sites, including Essen University Hospital in Germany, to accelerate patient recruitment. The move follows regulatory approval of an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026